Novel Implications of MicroRNAs, Long Non-coding RNAs and Circular RNAs in Drug Resistance of Esophageal Cancer

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Dec 9

PMID 34881242

Citations 6

Authors

Ling Wei

Jujie Sun

Nasha Zhang

Yue Shen

Teng Wang

Zengjun Li

Ming Yang

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer is the eighth most common malignancy and the sixth leading cause of cancer-related deaths worldwide. Chemotherapy based on platinum drugs, 5-fluorouracil, adriamycin, paclitaxel, gemcitabine, and vinorelbine, as well as targeted treatment and immunotherapy with immune checkpoint inhibitors improved the prognosis in a portion of patients with advanced esophageal cancer. Unfortunately, a number of esophageal cancer patients develop drug resistance, resulting in poor outcomes. Multiple mechanisms contributing to drug resistance of esophageal cancer have been reported. Notably, non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), have been identified to play crucial roles in modulating esophageal cancer drug resistance. In the present review, we highlight the underlying mechanisms how miRNAs, lncRNAs, and circRNAs impact the drug resistance of esophageal cancer. Several miRNAs, lncRNAs, and circRNAs may have potential clinical implications as novel biomarkers and therapeutic targets for esophageal cancer.

Citing Articles

Circular RNA promoted tumorigenesis and osimertinib resistance in lung adenocarcinoma via a circular RNA-microRNA network.

Hao Z, Feng F, Wang Q, Wang Y, Li J, Huang J J Thorac Dis. 2025; 16(12):8754-8770.

PMID: 39831223 PMC: 11740053. DOI: 10.21037/jtd-2024-2144.

Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer.

Yu S, Wang M, Zhang H, Guo X, Qin R J Cell Mol Med. 2024; 28(12):e18444.

PMID: 38924205 PMC: 11196374. DOI: 10.1111/jcmm.18444.

Current trends and future prospects of drug repositioning in gastrointestinal oncology.

Fatemi N, Karimpour M, Bahrami H, Zali M, Chaleshi V, Riccio A Front Pharmacol. 2024; 14:1329244.

PMID: 38239190 PMC: 10794567. DOI: 10.3389/fphar.2023.1329244.

Roles of circRNA dysregulation in esophageal squamous cell carcinoma tumor microenvironment.

Li J, Song Y, Cai H, Zhou B, Ma J Front Oncol. 2023; 13:1153207.

PMID: 37384299 PMC: 10299836. DOI: 10.3389/fonc.2023.1153207.

Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway.

Tan R, Liu J, Wang J, Zhang W, He M, Zhang Y Sci Rep. 2023; 13(1):5363.

PMID: 37005451 PMC: 10067833. DOI: 10.1038/s41598-023-32607-3.

References

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

Longley D, Harkin D, Johnston P . 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3(5):330-8. DOI: 10.1038/nrc1074. View

Zhu Y, Zhang Y, Li X, Su Y, Wang N, Chen M . Downregulation of miR‑106b‑3p increases sensitivity to cisplatin in esophageal cancer cells by targeting TGM3. Mol Med Rep. 2021; 23(6). DOI: 10.3892/mmr.2021.12110. View

Stroes C, Schokker S, Creemers A, Molenaar R, Hulshof M, van der Woude S . Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. J Clin Oncol. 2019; 38(5):462-471. PMC: 7007286. DOI: 10.1200/JCO.19.01814. View

Lin C, Li H, Liu Y, Kuo P, Wang W, Lin F . High-CLDN4 ESCC cells harbor stem-like properties and indicate for poor concurrent chemoradiation therapy response in esophageal squamous cell carcinoma. Ther Adv Med Oncol. 2019; 11:1758835919875324. PMC: 6767752. DOI: 10.1177/1758835919875324. View

Zhao Y, Ma K, Yang S, Zhang X, Wang F, Zhang X . MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol. 2018; 53(2):644-658. PMC: 6017156. DOI: 10.3892/ijo.2018.4409. View

Chen G, Peng J, Zhu W, Tao G, Song Y, Zhou X . Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy. Med Oncol. 2014; 31(11):263. DOI: 10.1007/s12032-014-0263-6. View

Yang Y, Liu G, Yuan D, Li C, Xue M, Chen L . Influence of exosome-derived miR-21on chemotherapy resistance of esophageal cancer. Eur Rev Med Pharmacol Sci. 2019; 23(4):1513-1519. DOI: 10.26355/eurrev_201902_17109. View

Pan W, Zhang N, Liu W, Liu J, Zhou L, Liu Y . The long noncoding RNA suppresses hepatocarcinogenesis by epigenetically activating the tumor suppressor . J Biol Chem. 2018; 293(44):17154-17165. PMC: 6222094. DOI: 10.1074/jbc.RA118.003055. View

10.

Lopez A, Harada K, Chen H, Bhutani M, Weston B, Lee J . Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore). 2020; 99(9):e19295. PMC: 7478597. DOI: 10.1097/MD.0000000000019295. View

11.

Komatsu S, Ichikawa D, Kawaguchi T, Takeshita H, Miyamae M, Ohashi T . Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget. 2016; 7(38):62034-62048. PMC: 5308709. DOI: 10.18632/oncotarget.11500. View

12.

Zou F, Yang S, Li W, Liu C, Liu X, Hu C . circRNA_001275 upregulates Wnt7a expression by competitively sponging miR‑370‑3p to promote cisplatin resistance in esophageal cancer. Int J Oncol. 2020; 57(1):151-160. PMC: 7252462. DOI: 10.3892/ijo.2020.5050. View

13.

Sun F, Zhang C, Ma D, Wang K . MicroRNA-544 inhibits esophageal squamous cell carcinoma cell proliferation and enhances sensitivity to cisplatin by repressing E2F transcription factor 5. Oncol Lett. 2019; 18(4):4203-4209. PMC: 6757299. DOI: 10.3892/ol.2019.10749. View

14.

Qu F, Wang L, Wang C, Yu L, Zhao K, Zhong H . Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis. Cancer Cell Int. 2021; 21(1):273. PMC: 8141117. DOI: 10.1186/s12935-021-01984-y. View

15.

Chen L . The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016; 17(4):205-11. DOI: 10.1038/nrm.2015.32. View

16.

Guo X, Li S, Zhu X, Dou Q, Liu D . Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer. Cancer Chemother Pharmacol. 2018; 82(3):383-394. DOI: 10.1007/s00280-018-3627-3. View

17.

Wang Y, Zhao Y, Herbst A, Kalinski T, Qin J, Wang X . miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression. Ann Surg. 2016; 264(5):804-814. DOI: 10.1097/SLA.0000000000001928. View

18.

Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M . CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017; 8:13897. PMC: 5227099. DOI: 10.1038/ncomms13897. View

19.

Guo Y, Jia Y, Wang S, Liu N, Gao D, Zhang L . Downregulation of MUTYH contributes to cisplatin‑resistance of esophageal squamous cell carcinoma cells by promoting Twist‑mediated EMT. Oncol Rep. 2019; 42(6):2716-2727. DOI: 10.3892/or.2019.7347. View

20.

Yang X, Song J, Cheng Y, Wu W, Bhagat T, Yu Y . Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut. 2013; 63(6):881-90. PMC: 4612639. DOI: 10.1136/gutjnl-2013-305266. View